Novel Approaches to Targeting Visceral and Hepatic Adiposities in HIV-Associated Lipodystrophy.
Visceral and hepatic adiposities have been associated with both cardiovascular and liver disease and are of concern in HIV-infected persons in the modern era of combination antiretroviral therapy (ART). The development of therapeutic targets to reduce visceral and hepatic adiposities in HIV-infected persons has been slow, because of early reports that attributed the excess adiposity to specific antiretroviral drugs. Visceral adiposity was initially thought to occur as part of a protease inhibitor-induced "HIV-associated lipodystrophy syndrome." Subsequent studies show that visceral adiposity is likely a result of effective ART, recovery of health, and the normal aging process. Visceral adiposity is an established risk factor for hepatic adiposity. Identifying drug targets for non-alcoholic fatty liver disease is under active investigation. The present review summarizes the recent literature on the pathogenesis of visceral and hepatic adiposities in HIV-infected persons, current therapeutic strategies, and novel interventions in HIV-infected and uninfected persons.
Department of Medicine, University of California, San Francisco, CA, 94143, USA. ptien@ucsf.edu.|Medical Service, Department of Veterans Affairs Medical Center, San Francisco, 4150 Clement Street, 111W, San Francisco, CA, 94121, USA. ptien@ucsf.edu.
Phyllis C
PC
Tien
D050154:Adiposity; D000818:Animals; D002318:Cardiovascular Diseases / Q000150:complications; D039682:HIV-Associated Lipodystrophy Syndrome / Q000188:drug therapy*; D006801:Humans; D065626:Non-alcoholic Fatty Liver Disease / Q000188:drug therapy*; D012307:Risk Factors
Cardiovascular disease; HIV; Hepatic steatosis; Lipodystrophy; Non-Alcoholic fatty liver disease; Visceral adiposity